Works matching IS 1007385X AND DT 2023 AND VI 30 AND IP 6

Results: 12

Immune-related ureteritis/cystitis caused by lung adenocarcinoma treated with combination of sintilimab and bevacizumab: a case report and literature review.

Published in:: Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 533, doi. 10.3872/j.issn.1007-385x.2023.06.012
Publication type:: Article

Progress in the application of injectable hydrogel delivery system in local immunotherapy of tumors.

Published in:: Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 523, doi. 10.3872/j.issn.1007-385x.2023.06.010
Publication type:: Article

Full-course management of therapy based on immune checkpoint inhibitors for advanced non-small cell lung cancer.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 455, doi. 10.3872/j.issn.1007-385x.2023.06.001

By:

GUAN Yaping;
WANG Jun

Publication type:

Article

Research progress in the relationship between intestinal microflora homeostasis and hepatocellular carcinoma.

Published in:: Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 528, doi. 10.3872/j.issn.1007-385x.2023.06.011
Publication type:: Article

Advances in the role of oncolytic adenovirus in tumor biotherapy.

Published in:: Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 517, doi. 10.3872/j.issn.1007-385x.2023.06.009
Publication type:: Article

Advances in the relationship between GSDMD-mediated pyroptosis and tumor development.

Published in:: Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 511, doi. 10.3872/j.issn.1007-385x.2023.06.008
Publication type:: Article

Clinical efficacy and safety of tumor-specific individualized multi-target DC-CIK in the treatment of advanced non-small cell lung cancer.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 505, doi. 10.3872/j.issn.1007-385x.2023.06.007

By:

MA Lihua;
WANG Jing;
LYU Shujie;
SHU Yan;
LI Wenming;
HE Yuan;
ZHANG Yan;
ZHAO Hua;
SHI Ruifang;
WANG Zhongda;
WANG Zixuan;
ZHU Yue;
YAO Lu;
JIA Shaochang;
JIANG Longwei

Publication type:

Article

INHBA-AS1 affects ornithine metabolism and EMT process of cervical cancer HeLa cells through c-Myc/SCD pathway.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 497, doi. 10.3872/j.issn.1007-385x.2023.06.06

By:

HUANG Huan;
LI Chun;
SONG Yu;
XU Yuanping;
HUANG Hongli;
LU Jingquan;
YANG Yi

Publication type:

Article

Effect of high expression of GSDME in nasopharyngeal carcinoma tissues on immune infiltration of tumor microenvironment and patient prognosis.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 489, doi. 10.3872/j.issn.1007-385x.2023.06.005

By:

DING Yi;
LI Kunfang;
WANG Ran;
ZHANG Juanning;
YUAN Poyun;
BI Xinman;
YU Jishuang;
QU Yanlin

Publication type:

Article

Characteristics and functions of long-term passaged human umbilical cord mesenchymal stem cells.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 482, doi. 10.3872/j.issn.1007-385x.2023.06.004

By:

HUANG Lijie;
XIE Yunqing;
LIN Xiaowei;
CHEN Wei;
ZHENG Qiuhong;
YING Mingang

Publication type:

Article

Epigenetic modification-mediated inhibition of SOSTDC1 expression promotes malignant biological behaviors in cervical cancer cells.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 473, doi. 10.3872/j.issn.1007-385x.2023.06.003

By:

LIN Wansong;
GUO Aihua;
CHEN Shuping;
WANG Yang;
HUANG Tianying;
FENG Mei;
YE Yunbin

Publication type:

Article

Preparation of liposome coated hollow copper sulfide nano-enzyme and their combined laser irradiation to against melanoma B16-F10 cells.

Published in:

Chinese Journal of Cancer Biotherapy, 2023, v. 30, n. 6, p. 464, doi. 10.3872/j.issn.1007-385x.2023.06.002

By:

ZHANG Mengya;
ZHOU Jingsheng;
WANG Zhen;
XIN Zhongyuan;
XU Kehao;
REN Yufei;
CHEN Cuimin;
LIANG Hao;
ZHANG Tinglin;
GAO Jie

Publication type:

Article